The Chain: Protein Engineering Podcast
The Chain explores the lives, careers, research, and discoveries of protein engineers and scientists, the impact their work is having on the field, and where the industry is headed. Tune in to stay up-to-date on the newest advancements and to hear the stories that are impacting the world of biologics.
The Chain: Protein Engineering Podcast
Episode: 57 - The Future of Bispecific Antibody Drug Conjugates With Rakesh Dixit, Ph. D.
•
Cambridge Healthtech Institute
•
Season 3
•
Episode 57
Bispecific antibody drug conjugates (ADCs) have been undergoing a renaissance in recent years. As big pharma continues to express more interest, what can the field expect for the future of ADCs? In this episode of The Chain, Nimish Gera, Ph. D., Vice President of Biologics of Mythic Therapeutics, speaks with Rakesh Dixit, Ph. D., President & CEO of Bionavigen, about his thoughts on the future of bispecific ADCs, what to keep in mind when selecting targets, and how to choose the right payload. Dr. Dixit also shares his 35 years of experience with top biotech and pharmaceutical companies, including Merck, J&J, and AstraZeneca, and how he is using his expertise to advise companies with their drug development programs.